<DOC>
	<DOC>NCT02128308</DOC>
	<brief_summary>This study aims to investigate the pharmacokinetic characteristics of second-line anti-tuberculosis agents after oral/intramuscular administration in healthy male volunteers.</brief_summary>
	<brief_title>Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<mesh_term>Prothionamide</mesh_term>
	<mesh_term>Streptomycin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Kanamycin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>healthy male subject aged 20 to 50 at screening a body weight in the range of 55 kg (inclusive) to 90 kg (inclusive) with ideal body weight range of 19.0 to 26.0 subjects who decide to participate voluntarily and write a informed consent form subjects who have clinically significant disease of cardiovascular, respiratory, renal, endocrinological, hematological, gastrointestinal, neurological(central nervous system), psychiatric disorders or malignant tumor subject judged not eligible for study participation by investigator.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Antituberculosis agents</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>